Mirum Pharmaceuticals（MIRM）株式概要
ミルーム・ファーマシューティカルズ社はバイオ医薬品会社で、衰弱性の希少疾患や希少疾病に対する新規治療薬の開発と商業化に注力している。 詳細
MIRM Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Mirum Pharmaceuticals, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$100.67 |
| 52週高値 | US$114.99 |
| 52週安値 | US$42.89 |
| ベータ | 0.52 |
| 1ヶ月の変化 | 7.86% |
| 3ヶ月変化 | -4.27% |
| 1年変化 | 128.54% |
| 3年間の変化 | 286.15% |
| 5年間の変化 | 526.84% |
| IPOからの変化 | 662.07% |
最新ニュース
ナラティブの更新 • May 18
MIRM: 2026 PSC Readout Will Reshape Long Term Earnings Outlook
Analysts have raised their average price target for Mirum Pharmaceuticals from about $140 to roughly $177, citing updated assumptions around revenue growth, higher profit margins, and a slightly lower discount rate in their models. Analyst Commentary Bullish analysts have been steadily lifting their price targets on Mirum Pharmaceuticals, pointing to what they see as solid execution, supportive guidance, and a healthy pipeline of potential catalysts.Seeking Alpha • May 12
Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise
Summary Mirum Pharmaceuticals is evolving into a rare disease commercialization platform with multiple late-stage assets and robust commercial execution. MIRM raised 2026 net product sales guidance to $660–$680M, reflecting strong visibility and momentum, especially from LIVMARLI and bile acid products. The BlueJay acquisition and late-stage programs in HDV, PSC, and FOP create a catalyst-rich period, supporting the premium valuation versus sector peers. I see MIRM as a high-growth, catalyst-driven mid-cap biotech with sufficient cash reserves and a platform poised for multiple product launches. Read the full article on Seeking AlphaRecent updates
ナラティブの更新 • May 18
MIRM: 2026 PSC Readout Will Reshape Long Term Earnings Outlook
Analysts have raised their average price target for Mirum Pharmaceuticals from about $140 to roughly $177, citing updated assumptions around revenue growth, higher profit margins, and a slightly lower discount rate in their models. Analyst Commentary Bullish analysts have been steadily lifting their price targets on Mirum Pharmaceuticals, pointing to what they see as solid execution, supportive guidance, and a healthy pipeline of potential catalysts.Seeking Alpha • May 12
Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise
Summary Mirum Pharmaceuticals is evolving into a rare disease commercialization platform with multiple late-stage assets and robust commercial execution. MIRM raised 2026 net product sales guidance to $660–$680M, reflecting strong visibility and momentum, especially from LIVMARLI and bile acid products. The BlueJay acquisition and late-stage programs in HDV, PSC, and FOP create a catalyst-rich period, supporting the premium valuation versus sector peers. I see MIRM as a high-growth, catalyst-driven mid-cap biotech with sufficient cash reserves and a platform poised for multiple product launches. Read the full article on Seeking Alpha
ナラティブの更新 • May 04
MIRM: Fair Value Views Turn On 2026 PSC Readout
Analysts have lifted the average price target for Mirum Pharmaceuticals from $106.60 to about $129.73, reflecting updated assumptions on revenue growth, margins and future P/E multiples. Analyst Commentary Recent Street research has been active on Mirum Pharmaceuticals, with several firms revisiting their models and resetting price targets.ナラティブの更新 • Apr 19
MIRM: 2026 PSC Readout Will Reframe Long Term Earnings Power
Analysts recently lifted Mirum Pharmaceuticals' average price target by several dollars to a range of about $117 to $130, citing updated models that reflect slightly higher revenue growth and profit margin assumptions, along with a modestly higher discount rate and continued focus on upcoming clinical and commercial catalysts. Analyst Commentary Bullish analysts have been steadily lifting their valuation work on Mirum Pharmaceuticals, pushing price targets into a band that runs roughly from the high $110s to about $130.ナラティブの更新 • Apr 05
MIRM: 2026 PSC Readout And Guidance Will Reset Earnings Power Narrative
Analysts have lifted their average price targets on Mirum Pharmaceuticals by several dollars into a range that now runs into the low to mid $100s, citing updated models that incorporate higher revenue growth, stronger profit margins and still elevated but slightly lower future P/E assumptions. Analyst Commentary Recent research has leaned clearly positive on Mirum Pharmaceuticals, with several bullish analysts lifting price targets into a clustered range around the low to mid US$100s.ナラティブの更新 • Mar 22
MIRM: 2026 Clinical Readouts And Guidance Will Reframe Earnings Power Narrative
Analysts have lifted their average price targets on Mirum Pharmaceuticals into a roughly $117 to $130 range, citing in line reported revenue, reiterated guidance, continued commercial traction in Livmarli and the bile acid portfolio, as well as upcoming clinical catalysts as key supports for the updated views. Analyst Commentary Recent Street research on Mirum Pharmaceuticals has leaned positive, with multiple bullish analysts revisiting their models and adjusting price targets in a tight cluster around the low to mid $120s.ナラティブの更新 • Mar 07
MIRM: 2026 Pipeline Catalysts And Guidance Will Reshape Earnings Power Narrative
Analysts have lifted their aggregate price targets for Mirum Pharmaceuticals by several dollars into a roughly $117 to $130 range, reflecting updated views on revenue potential, margin expectations and future P/E multiples following recent earnings, guidance and pipeline commentary. Analyst Commentary Recent Street research has tilted clearly positive, with a cluster of bullish analysts lifting their targets into the low to mid US$100s after Mirum's latest earnings, guidance and pipeline updates.
ナラティブの更新 • Feb 21
MIRM: Elevated Expectations Will Hinge On Upcoming PSC Trial Outcome
Analysts have lifted their fair value estimate for Mirum Pharmaceuticals to $95.00 from $56.92, citing higher modeled revenue growth, improved profit margin assumptions, and reinforced confidence in Livmarli and the broader bile acid portfolio, following recent price target increases and new Outperform initiations across the Street. Analyst Commentary Recent Street research around Mirum Pharmaceuticals has centered on the commercial trajectory for Livmarli, the broader bile acid portfolio, and upcoming clinical milestones.ナラティブの更新 • Feb 07
MIRM: Busy 2026 Pipeline And Guidance Will Reframe Execution Expectations
Narrative Update on Mirum Pharmaceuticals The analyst price target for Mirum Pharmaceuticals has moved from US$89 to US$140. Analysts cite higher modeled fair value, despite adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions following recent price target increases across several research firms.分析記事 • Jan 28
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25%
Despite an already strong run, Mirum Pharmaceuticals, Inc. ( NASDAQ:MIRM ) shares have been powering on, with a gain of...ナラティブの更新 • Jan 23
MIRM: Fair Value Tied To 2026 PSC Data And Execution Risks
Analysts have nudged their fair value estimate for Mirum Pharmaceuticals higher from $103.10 to $106.60, citing recently raised Street price targets that reflect stronger than expected preliminary results, updated guidance, and continued confidence around Livmarli and the late stage pipeline. Analyst Commentary Street research on Mirum Pharmaceuticals has centered on the recent preliminary results, guidance, and the outlook for Livmarli and the late stage pipeline, with several firms updating their models and fair value assumptions.ナラティブの更新 • Jan 08
MIRM: Shares Should Benefit From 2026 PSC Volixibat Data Trigger
Narrative Update The analyst price target for Mirum Pharmaceuticals has been raised to $95, up from $81. Analysts point to Livmarli's recent sales performance and upcoming late stage volixibat readouts in primary sclerosing cholangitis and primary biliary cholangitis as key drivers of their updated views.ナラティブの更新 • Dec 25
MIRM: Shares Should Climb On 2026 PSC Volixibat Pivotal Readout
Analysts have raised their price target on Mirum Pharmaceuticals to $103.10 from $95.20, citing Livmarli's sustained commercial traction and the potential for volixibat's late stage data to drive the next phase of growth toward profitability. Analyst Commentary Recent research updates reflect a generally constructive stance on Mirum Pharmaceuticals, with price targets moving higher as Livmarli execution remains solid and expectations build around the volixibat pipeline.ナラティブの更新 • Dec 11
MIRM: Shares Will Rise On 2026 Pivotal PSC Volixibat Readout
Mirum Pharmaceuticals' analyst price target has been lifted from $87.99 to $95.20 as analysts highlight Livmarli's strong commercial trajectory, an improving path to profitability, and the potential next wave of growth from late stage volixibat data expected in 2026. Analyst Commentary Bullish analysts see the latest price target increases as a reflection of Mirum's strengthening commercial execution and expanding pipeline visibility.ナラティブの更新 • Nov 27
MIRM: Shares Will Surge On Pivotal Late-Stage Data Readout In 2026
Mirum Pharmaceuticals' analyst price target has increased from $86.09 to $87.99. This reflects analysts' optimism about continued strong sales, upcoming clinical milestones, and anticipated profitability improvements.ナラティブの更新 • Nov 13
MIRM: Shares Will Rally On Pivotal Clinical Data Expected In 2026
Analysts have raised their price target for Mirum Pharmaceuticals from $83.55 to $86.09 per share, citing continued strong performance for Livmarli and optimism around late-stage clinical catalysts expected over the next two years. Analyst Commentary Recent research updates reflect a broadly positive outlook for Mirum Pharmaceuticals, with several analysts raising their price targets and emphasizing key growth drivers for the company.ナラティブの更新 • Oct 30
Upcoming Clinical Milestones Will Drive Rare Disease Pipeline Expansion Into 2026
Mirum Pharmaceuticals' analyst price target has been raised, with the fair value estimate increasing slightly to $83.55 from $83. Analysts cite continued strong Livmarli performance and upcoming clinical milestones as key factors supporting this upward revision.分析記事 • Oct 16
Mirum Pharmaceuticals (NASDAQ:MIRM) Is Carrying A Fair Bit Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...ナラティブの更新 • Oct 15
Genetic Testing And International Expansion Will Broaden Rare Disease Markets
Analysts have raised their fair value price target for Mirum Pharmaceuticals from $81 to $83, citing higher revenue growth forecasts and strong performance in recent quarters. Analyst Commentary Analysts have expressed a largely positive view on Mirum Pharmaceuticals' outlook, citing several drivers of growth and ongoing execution.ナラティブの更新 • Sep 25
Genetic Testing And International Expansion Will Broaden Rare Disease Markets
Analysts raised Mirum Pharmaceuticals’ price target from $78.27 to $81.00, citing surging Livmarli sales, strong Q2 results, a robust and expanding rare disease pipeline, and continued commercial execution. Analyst Commentary Bullish analysts meaningfully increased Livmarli sales forecasts following Mirum's strong Q2 earnings beat and upwardly revised 2025 guidance.分析記事 • Aug 11
Analysts Just Shipped A Substantial Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates
Mirum Pharmaceuticals, Inc. ( NASDAQ:MIRM ) shareholders will have a reason to smile today, with the analysts making...ナラティブの更新 • Aug 08
Genetic Testing And International Expansion Will Broaden Rare Disease Markets
Mirum Pharmaceuticals’ modest target price increase reflects improved consensus revenue growth forecasts, though this is partially offset by a slight expansion in the future P/E multiple, resulting in a marginal upward revision of the fair value to $77.20. What's in the News Mirum Pharmaceuticals raised its 2025 revenue guidance to $490 million to $510 million.新しいナラティブ • May 09
FDA And Japanese Approvals Will Open New Markets
Strong revenue growth and recent regulatory approvals are set to expand market reach and positively impact future revenues.Seeking Alpha • Mar 24
Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like
Summary Mirum Pharmaceuticals, Inc.'s stock has risen over 50% in the past year, despite a recent 15% dip due to market volatility. The company reported strong Q4 results in late February with a 43% Y/Y revenue increase, driven by Livmarli's sales growth. Analysts unanimously rate Mirum as a Buy and expect significant revenue growth and reduced losses. The company should be cash flow positive by the end of this fiscal year. Mirum's pipeline includes promising candidates like Volixibat and MRM-3379, both with billion-dollar potential, supporting a positive long-term outlook. An updated analysis around MIRM stock follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jan 08
Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)
Summary The biotech industry is primed for increased M&A activity due to low valuations and big pharma's need to offset patent losses. Mirum Pharmaceuticals, with three approved drugs and a strong pipeline, is a possible prime takeover candidate with significant growth potential. MIRM's stock shows strong upward momentum, supported by impressive sales growth, positive cash flow, and a clear path to profitability. Wall Street is bullish on MIRM, projecting a 50% upside to $63. We are slightly (a lot) more bullish right now at $64.40 (two years from now at $82.40). Read the full article on Seeking AlphaSeeking Alpha • Dec 25
Mirum Pharma: Buy At Dips For Volixibat Potential
Summary Mirum Pharma has three approved products and a promising pipeline, with volixibat showing superior interim data for PBC compared to competitors. It is a buy for volixibat's potential, which is 2-3 years away from approval, but supported in the interim by the other approved drugs. Financially, Mirum has a market cap of $2bn, a cash balance of $294mn, and a cash runway of over 12-15 quarters. The key risk lies in the intense competition in the PBC space and the wait for volixibat's approval. Despite trading at the higher end of its 52-week range, Mirum is an attractive buy on dips. Read the full article on Seeking AlphaSeeking Alpha • Oct 04
Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish
Summary Mirum Pharmaceuticals, Inc.'s stock has risen >150% since 2021, driven by its rare disease treatments, but its current valuation may be overstated given ongoing losses and competitive pressures. The company's key revenue drivers include Livmarli, Cholbam, and Chenodal, with potential peak revenues of around $450M, but profitability remains elusive. Volixibat shows promise in Phase 2b trials for PSC and PBC, but approval is unlikely before 2027, and competition is intense. Mirum's cash burn and lengthy approval timelines suggest a potential downward price correction, with a lower valuation likely in 2025. Read the full article on Seeking AlphaSeeking Alpha • Jul 17
Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition
Summary Mirum Pharmaceuticals develops therapies for rare liver diseases, focusing on bile acid regulation. Key products include Livmarli, Cholbam, and Chenodal, with Chenodal recently completing Phase 3 trials for CTX. MIRM's pipeline also has Volixibat in Phase 2b trials for PSC and PBC. MIRM's recent acquisition of Cholbam and Chenodal from Travere Therapeutics is strategically significant. I believe that despite trading at a premium, MIRM's growth prospects and strong fundamentals justify a "buy" rating. Read the full article on Seeking AlphaSeeking Alpha • Apr 22
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Summary The FDA approved Mirum Pharmaceuticals, Inc.'s Limvarli for treatment of cholestatic pruritus in patients with Progressive Familial Intrahepatic Cholestasis; Potential for further label expansion in younger patients possible due to positive MARCH study. Interim results from VANTAGE study using Volixibat for patients with PBC are expected 1st half of 2024; The global primary biliary cholangitis therapeutics market is projected to reach $1.4 billion by 2032. Interim results from VISTAS study using Volixibat for patients with PSC expected 1st half 2024; The global Primary Sclerosing Cholangitis market is expected to reach $586.8 million by 2034. Total net product revenues of $178.9 million for the full-year ending December 2023, compared to the prior year ending December 2022 with net product revenues of only $75.1 million in sales. Read the full article on Seeking AlphaSeeking Alpha • Mar 05
Mirum Pharmaceuticals: Advancing On Several Key Fronts
Summary Mirum Pharmaceuticals delivered solid Q4 results last week, with projected sales growth of around 70% for fiscal year 2024. The company's primary growth driver is Livmarli, an oral solution approved for the treatment of cholestatic pruritus for Alagille syndrome patients. MIRM has other promising compounds in its pipeline, including Volixibat, and is projected to become profitable in FY2025. An updated analysis around Mirum Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha株主還元
| MIRM | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -9.6% | -3.0% | -0.3% |
| 1Y | 128.5% | 32.9% | 26.7% |
業界別リターン: MIRM過去 1 年間で32.9 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: MIRM過去 1 年間で26.7 % の収益を上げたUS市場を上回りました。
価格変動
| MIRM volatility | |
|---|---|
| MIRM Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: MIRM 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: MIRMの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2018 | 418 | Chris Peetz | www.mirumpharma.com |
ミルーム・ファーマシューティカルズ社はバイオ医薬品企業で、衰弱性の希少疾患や希少疾病に対する新規治療薬の開発と商業化に注力している。同社の主要製品候補であるLIVMARLI（maralixibat）は、経口投与が可能で吸収の少ない回腸胆汁酸トランスポーター（IBAT）阻害剤であり、米国および海外でアラジール症候群患者の胆汁性そう痒症の治療薬として承認されている。また、単一酵素欠損による胆汁酸合成障害の小児および成人患者の治療薬として、またペルオキシソーム生合成障害-Zellwegerスペクトラム障害、Smith-Lemli-Opitz症候群を含むペルオキシソーム障害患者の補助治療薬として承認されているコール酸カプセル剤Cholbamの商業化にも携わっている；胆嚢の放射線透過性結石の治療薬として承認されており、脳腱性黄色腫症の治療薬として開発中である。また、胆汁うっ滞性肝疾患の治療薬としてフェーズ2b試験中のIBAT阻害剤Volixibat、慢性HDV感染症の治療薬としてフェーズ2試験中のBrelovitug、FXSの治療薬としてフェーズ2試験中のMRM-3379を開発している。同社は、Shire International GmbHとの提携契約、Pfizer Inc.、Sanofi-Aventis Deutschland GmbH、Novartis Pharma AG、Lonza Ltd.、Enthorin Therapeutics, LLCおよびDart Neuroscience LLCとのライセンス契約、Asklepion Pharmaceuticals, LLCとの資産購入契約、LGM Pharmaとのライセンスおよび製造契約、Travere Therapeutics, Inc.との資産購入契約を締結している。同社は2018年に法人化され、カリフォルニア州フォスターシティに本社を置いている。
Mirum Pharmaceuticals, Inc. 基礎のまとめ
| MIRM 基礎統計学 | |
|---|---|
| 時価総額 | US$5.91b |
| 収益（TTM） | -US$798.84m |
| 売上高(TTM) | US$569.61m |
10.8x
P/Sレシオ-7.7x
PER（株価収益率MIRM は割高か？
公正価値と評価分析を参照収益と収入
| MIRM 損益計算書（TTM） | |
|---|---|
| 収益 | US$569.61m |
| 売上原価 | US$106.03m |
| 売上総利益 | US$463.58m |
| その他の費用 | US$1.26b |
| 収益 | -US$798.84m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -13.10 |
| グロス・マージン | 81.39% |
| 純利益率 | -140.24% |
| 有利子負債／自己資本比率 | 127.9% |
MIRM の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 01:20 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Mirum Pharmaceuticals, Inc. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23
| アナリスト | 機関 |
|---|---|
| Brian Skorney | Baird |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |